KIT can be bound and inhibited by class II tyrosine kinase inhibitors including imatinib, sunitinib, regorafenib and others. Type II inhibitors bind to the inactive conformation of the kinase and prevent its activation (reviewed in Roskoski, 2018; Abbaspour Babaei et al, 2016; Klug et al, 2018).
Roskoski, R
Abbaspour Babaei, M, Kamalidehghan, B, Saleem, M, Huri, HZ, Ahmadipour, F
Klug, LR, Kent, JD, Heinrich, MC
© 2020 Reactome
